首页> 外文期刊>Clinical oncology >Treatment of Glioblastoma Multiforme - The Oxford Cancer Centre Experience
【24h】

Treatment of Glioblastoma Multiforme - The Oxford Cancer Centre Experience

机译:多形性胶质母细胞瘤的治疗-牛津癌症中心的经验

获取原文
获取原文并翻译 | 示例
       

摘要

Sir - Glioblastoma multiforme (GBM) is an aggressive primary brain tumour. In 2005, a landmark European Organization for Research and Treatment of Cancer/ National Cancer Institute Canada (EORTC/NQC) trial showed that the addition of concomitant and adjuvant temozolomide to radical radiotherapy gives patients improved survival [1]. The presence of MGMT promoter hypermethylation silences the MGMT gene, thereby reducing resistance to alkylating agents. This is associated with longer survival in patients who receive alkylating agents and is also an independent prognostic factor [2].Herbert etui. [3] reported the experience of treating GBM in the Avon, Somerset, Wiltshire Cancer Services Network. Here we present the Oxford experience, which provides some insight into the use of pretreatment MGMT hypermethylation analysis to decide treatment.We reviewed 151 patients with GBM treated at the Oxford Cancer Centre over 3 years from 2006. Patients having chemoradiotherapy received 60 Gy in 30 fractions and temozolomide 75 mg/m2 daily for 42 days and six subsequent cycles 150-200 mg/m2 days 1-5 every 28 days.
机译:先生-多形胶质母细胞瘤(GBM)是一种侵略性的原发性脑肿瘤。 2005年,具有里程碑意义的欧洲癌症研究与治疗组织/加拿大国家癌症研究所(EORTC / NQC)进行的一项试验表明,根治性放疗中同时加用替莫唑胺和辅助用替莫唑胺可以提高患者的生存率[1]。 MGMT启动子高甲基化的存在使MGMT基因沉默,从而降低了对烷基化剂的抗性。这与接受烷化剂的患者更长的生存期相关,也是一个独立的预后因素[2]。Herbertetui。 [3]报告了在威尔特郡癌症服务网络的萨默塞特郡雅芳市治疗GBM的经验。在这里,我们将介绍牛津大学的经验,这为使用MGMT预处理进行甲基化分析来决定治疗方法提供了一些见识。我们对2006年开始在牛津癌症中心接受治疗的151例GBM患者进行了3年的回顾。接受放化疗的患者分30次接受60 Gy替莫唑胺每天75 mg / m2,持续42天,随后的六个周期为150-200 mg / m2天,每28天1-5。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号